Overview

Open-Label Hepatic Impairment Study

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This study will be conducted in Hepatitis C positive patients to determine whether the pharmacodynamic effects of PSI-7977 or PSI-352938 are similar to HCV-infected patients with normal hepatic function, which may allow inclusion of patients with cirrhosis and varying degrees of hepatic dysfunction in future clinical studies.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Sofosbuvir